GENinCode UK Ltd. (GB:GENI)
LSE:GENI
Want to see GB:GENI full AI Analyst Report?
GENI Stock Chart & Stats
2.20 p
0.20 p(5.56%)
At close: 4:00 PM EST
2.20 p
0.20 p(5.56%)
Day’s Range― - ―
52-Week Range0.85 p - 5.50 p
Previous CloseN/A
Volume6.76K
Average Volume (3M)1.99M
Market Cap
£7.15M
Enterprise Value1.77M
Total Cash (Recent Filing)£895.00K
Total Debt (Recent Filing)£146.00K
Price to Earnings (P/E)―
Beta-0.77
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume166,671
30 Day Avg. Volume1,986,185
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin TrendAn accelerating revenue growth rate paired with gross margin expansion to ~50% indicates improving unit economics and product traction. Sustained top-line growth with higher gross margins can absorb fixed costs more effectively and supports scalable profitability if operational leverage continues to improve.
Focused Clinical Product ModelA focused offering in genomic profiling and diagnostic reports for clinicians and labs creates specialized capabilities and client relationships. This clinical orientation raises barriers to entry, supports recurring institutional demand, and underpins durable revenue opportunities tied to healthcare workflows and testing adoption.
Low Absolute DebtRelatively small total debt keeps fixed financing obligations limited, preserving operational flexibility. Lower absolute leverage reduces near-term insolvency risk, allowing time to execute commercialization or cost-mitigation strategies and making external financing or partnerships less urgent than for highly leveraged peers.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicate ongoing cash burn that erodes runway and forces reliance on external funding. This constrains investment in sales, R&D, or scale-up initiatives, increases dilution or debt risk, and makes sustainable growth dependent on either faster revenue scaling or material cost reductions.
Eroded Equity / Weakened Balance SheetA sharp decline in equity reduces the company's buffer against losses and raises leverage metrics, narrowing strategic and financing options. With diminished equity, future fundraising may be more dilutive or costly, and the company is more exposed to shocks if operating losses persist, undermining medium-term stability.
Deep UnprofitabilityExtremely negative net and operating margins show the cost base far exceeds current revenue scale. Structural unprofitability implies the business needs substantial scale-up, pricing power, or cost restructuring to reach breakeven, presenting execution risk and likely continued funding needs over the coming months.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest share price was 0.85 p and its highest was 5.50 p in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is £7.15M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 105 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -0.01 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.01 p.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -0.01 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in GB:GENI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---